Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Generics Priced Higher Than Original Drugs Should Not Be Regarded as Generics: Korosho
February 15, 2010
- HSTTC Mediates Transfer of NCC-Developed Technology to MKI
February 15, 2010
- Only 2% of Current Non-Users to Start Prescribing Rasilez: SSRI
February 15, 2010
- Panel to Review Drugs, Indications That Need Development
February 15, 2010
- 3rd Candidate for JMA President
February 15, 2010
- Takeda to Work Out New Mid-Term Management Plan 1 Year Ahead of Schedule
February 15, 2010
- Daiichi Sankyo Applies for Laninamivir in Japan
February 15, 2010
- JAID Compiles Guidance for Selection of Anti-Flu Drugs
February 15, 2010
- Chugai Aims to Lead Market in 3 Fields: Mr Nagayama
February 15, 2010
- Urief Approved in Europe: Kissei
February 15, 2010
- Smoking Cessation Aids Should Be Covered by Insurance in Young Smokers
February 15, 2010
- US Sales of Prograf Down 17.6% Following Generic Entry
February 15, 2010
- Bendamustine Approved in Singapore: SymBio
February 15, 2010
- Kowa to Launch Livalo Soon in the US
February 15, 2010
- Banyu, Schering-Plough Copromote Mutual Products to Offer New Options for Asthma, Allergy
February 15, 2010
- Astellas to Enter PII for Antibody Drug for Ovarian Cancer
February 15, 2010
- Novartis Aims to Become Top-3 Oncology Company in Japan
February 15, 2010
- Daiichi Sankyo Begins Global PIII Trial for Edoxaban for Prevention of VTE
February 15, 2010
- NBI Aims at RLS to Account for 15% of BI-Sifrol Sales
February 15, 2010
- Application for Eritoran Postponed: Eisai
February 15, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…